AI Summary & Key Takeaways
AI InsightInfliximab has the advantage of showing rapid clinical response in the treatment of unstable psoriasis and generalized pustular psoriasis
📌 3 Key Takeaways
Abstract
Infliximab is a TNF-α inhibitor in the form of a chimeric monoclonal antibody. It received FDA approval in 2006 for the treatment of adult patients with severe chronic plaque psoriasis who developed side effects with conventional therapies or in whom these therapies were contraindicated or did not produce any response. Infliximab is administered via intravenous infusion, and infusion reactions are one of its common side effects. It is not suitable for intermittent treatment due to the high risk of infusion reaction, risk of developing antibodies, and loss of efficacy. Infliximab has the advantage of showing rapid clinical response in the treatment of unstable psoriasis and generalized pustular psoriasis
Özet
İnfliksimab, TNF-α inhibitörü olan şimerik bir monoklonal antikordur. Konvansiyonel tedavilerle yan etki gelişmiş, kontrendikasyon bulunan veya yanıtsız şiddetli kronik plak psoriasisi olan erişkin hastaların tedavisinde 2006 yılında FDA onayı almıştır. İnfliksimab intravenöz infüzyon yoluyla uygulanmaktadır ve infüzyon reaksiyonları sık görülen bir yan etkisidir. Artmış infüzyon reaksiyon riski, antikor gelişim riski ve etkinlik kaybı nedeniyle aralıklı tedavi için uygun değildir. İnfliksimab, stabil olmayan psoriasis ve generalize püstüler psoriasis tedavisinde hızlı klinik yanıt avantajına sahiptir.